UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 30, 2005



                           DRAGON PHARMACEUTICAL INC.
                           -------------------------
             (Exact name of registrant as specified in its charter)


          Florida                         0-27937                65-0142474
          -------                         -------                ----------
(State or Other Jurisdiction of   (Commission File Number)      (IRS Employer
         Incorporation)                                      Identification No.)

       1055 Hastings Street, Suite 1900
         Vancouver, British Columbia                     V6E 2E9
         ----------------------------                    -------
   (Address of Principal Executive Offices)             (Zip Code)


                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Section 7 - Regulation FD

     Item 7.01 Regulation FD Disclosure

     The Company  today  announced  that it proposes to offer on a best  efforts
basis up to $25 million of its  securities in a private  placement to accredited
investors. The type of securities,  price and completion of the proposed private
placement  will  depend  on,  among  other  things,  market  conditions.  It  is
anticipated  that the proceeds from the private  placement will be used to serve
as the working capital to ramp up the production of the newly operated  Chemical
division, to improve the Company's financial structure and to fund the Company's
EPO market  development  in Europe,  as well as the  relocation  of the  Biotech
facility  within  China.  The  securities  proposed to be offered in the private
placement  will  not be  registered  under  the  Securities  Act  or  any  state
securities  laws, and unless they are so registered,  may not be offered or sold
in the United  States  except  pursuant to an  exemption  from the  registration
requirements of the Securities Act and applicable state securities laws.

     This Form 8-K shall not constitute an offer to sell or the  solicitation of
an offer to buy any security and shall not constitute an offer,  solicitation or
sale in any  jurisdiction  in which such  offer,  solicitation  or sale would be
unlawful.

     Cautionary  Statement:  The Company's  statements in this Form 8-K that are
not  historical  facts,  and  that  relate  to  future  plans  or  events,   are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform Act of 1995.  These  forward-looking  statements  include the
Company's  intention to raise proceeds through the proposed offering and sale of
its  securities.  There can be no assurance  that the Company will  complete the
proposed  offering on the anticipated  terms or at all. The Company's ability to
complete  the  proposed  offering  will depend on,  among other  things,  market
conditions.  The Company does not  undertake the  obligation to publicly  revise
these forward looking statements to reflect subsequent events or circumstances.

Section 9 - Financial Statements and Exhibits

      Item 9.01 Financial Statements and Exhibits

             Exhibit No.      Exhibit Description
             ----------       -------------------

                 99           Press release dated March 30, 2005 titled Dragon
                              Pharmaceutical Announces Proposed Private Offering



                                       2
<PAGE>


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  March 30, 2005                   DRAGON PHARMACEUTICAL INC.


                                        /s/ Maggie Deng
                                        ---------------------------------------
                                        Maggie Deng
                                        Chief Operating Officer




                                       3
<PAGE>


                                  EXHIBIT INDEX

           Exhibit No.       Description
           -----------       -----------

               99            Press release dated March 30, 2005 titled Dragon
                             Pharmaceutical Announces Proposed Private Offering




                                       4
[{"type": "8-K", "sequence": "1", "filename": "for033005.txt", "description": "FOR33005", "secsgml_size_bytes": 5487}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICAL INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "05715871"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1", "zip": "V6E 2E9", "phone": "6046698817"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO", "state": "A1", "zip": "V6E 2E9"}, "former-company": {"former-conformed-name": "DRAGON PHARMACEUTICALS INC", "date-changed": "19991022"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 30, 2005

                           DRAGON PHARMACEUTICAL INC.
                           -------------------------
             (Exact name of registrant as specified in its charter)

          Florida                         0-27937                65-0142474
          -------                         -------                ----------
(State or Other Jurisdiction of   (Commission File Number)      (IRS Employer
         Incorporation)                                      Identification No.)

       1055 Hastings Street, Suite 1900
         Vancouver, British Columbia                     V6E 2E9
         ----------------------------                    -------
   (Address of Principal Executive Offices)             (Zip Code)

                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Section 7 - Regulation FD

     Item 7.01 Regulation FD Disclosure

     The Company  today  announced  that it proposes to offer on a best  efforts
basis up to $25 million of its  securities in a private  placement to accredited
investors. The type of securities,  price and completion of the proposed private
placement  will  depend  on,  among  other  things,  market  conditions.  It  is
anticipated  that the proceeds from the private  placement will be used to serve
as the working capital to ramp up the production of the newly operated  Chemical
division, to improve the Company's financial structure and to fund the Company's
EPO market  development  in Europe,  as well as the  relocation  of the  Biotech
facility  within  China.  The  securities  proposed to be offered in the private
placement  will  not be  registered  under  the  Securities  Act  or  any  state
securities  laws, and unless they are so registered,  may not be offered or sold
in the United  States  except  pursuant to an  exemption  from the  registration
requirements of the Securities Act and applicable state securities laws.

     This Form 8-K shall not constitute an offer to sell or the  solicitation of
an offer to buy any security and shall not constitute an offer,  solicitation or
sale in any  jurisdiction  in which such  offer,  solicitation  or sale would be
unlawful.

     Cautionary  Statement:  The Company's  statements in this Form 8-K that are
not  historical  facts,  and  that  relate  to  future  plans  or  events,   are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform Act of 1995.  These  forward-looking  statements  include the
Company's  intention to raise proceeds through the proposed offering and sale of
its  securities.  There can be no assurance  that the Company will  complete the
proposed  offering on the anticipated  terms or at all. The Company's ability to
complete  the  proposed  offering  will depend on,  among other  things,  market
conditions.  The Company does not  undertake the  obligation to publicly  revise
these forward looking statements to reflect subsequent events or circumstances.

Section 9 - Financial Statements and Exhibits

      Item 9.01 Financial Statements and Exhibits

             Exhibit No.      Exhibit Description
             ----------       -------------------

                 99           Press release dated March 30, 2005 titled Dragon
                              Pharmaceutical Announces Proposed Private Offering

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  March 30, 2005                   DRAGON PHARMACEUTICAL INC.

                                        /s/ Maggie Deng
                                        ---------------------------------------
                                        Maggie Deng
                                        Chief Operating Officer

                                       3
EXHIBIT INDEX

           Exhibit No.       Description
           -----------       -----------

               99            Press release dated March 30, 2005 titled Dragon
                             Pharmaceutical Announces Proposed Private Offering

                                       4